8-K: Grace Therapeutics Submits New Drug Application for GTx-104 to FDA, Signaling Potential Breakthrough in aSAH Treatment

Grace Therapeutics, Inc. announced the submission of its New Drug Application for GTx-104 to the U.S. Food and Drug Administration, a significant step towards addressing unmet medical needs in aneurysmal subarachnoid hemorrhage patients.

Summary

• Grace Therapeutics, Inc. has submitted a New Drug Application (NDA) for GTx-104 to the U.S. Food and Drug Administration (FDA).
• GTx-104 is a novel, injectable formulation of nimodipine developed for IV infusion to treat aneurysmal subarachnoid hemorrhage (aSAH) patients.
• The NDA submission includes a comprehensive data package, featuring positive results from the Company's Phase 3 STRIVE-ON safety trial.
• The STRIVE-ON trial met its primary endpoint, demonstrating a 19% reduction in clinically significant hypotension for GTx-104 patients (28%) compared to those receiving oral nimodipine (35%).
• Other favorable outcomes for GTx-104 included 54% of patients achieving 95% or higher relative dose intensity (RDI) versus only 8% for oral nimodipine, and 29% more patients experiencing favorable functional outcomes at 90 days.
• Patients treated with GTx-104 also showed fewer intensive care unit (ICU) readmissions, ICU days, and ventilator days.
• The NDA submission has the potential to trigger the exercise of up to $7.6 million in warrants issued as part of a September 2023 private placement, exercisable at $3.003 per share.
• GTx-104 has received Orphan Drug Designation from the FDA, which provides seven years of marketing exclusivity in the United States upon approval.
• The Company believes its U.S. and international patent estate will protect the market value of GTx-104 beyond marketing exclusivity.

Sentiment

Score: 8

Explanation: The document announces a significant positive milestone (NDA submission) for a lead drug candidate with positive Phase 3 trial results, addressing a high unmet medical need. It also highlights potential capital inflow and strong intellectual property, indicating a very favorable outlook despite a minor negative point about non-drug-related deaths.

Positives

• Submission of a New Drug Application (NDA) for GTx-104 to the FDA, marking a major regulatory milestone.
• Positive results from the Phase 3 STRIVE-ON safety trial, which met its primary endpoint and provided evidence of clinical benefit.
• GTx-104 demonstrated a 19% reduction in clinically significant hypotension compared to oral nimodipine (28% vs 35%).
• Improved relative dose intensity (RDI) for GTx-104 (54% of patients at 95% or higher RDI) compared to oral nimodipine (8%).
• 29% more patients on GTx-104 had favorable functional outcomes at 90 days.
• Fewer intensive care unit (ICU) readmissions, ICU days, and ventilator days for GTx-104 patients.
• Adverse events were comparable between treatment arms, with no new safety issues identified for GTx-104.
• GTx-104 has Orphan Drug Designation from the FDA, providing seven years of marketing exclusivity in the U.S. upon approval.
• The Company possesses a strong U.S. and international patent estate (over 40 granted and pending patents) expected to protect GTx-104's market value.
• Potential to trigger the exercise of up to $7.6 million in warrants, providing a significant capital infusion to the company.
• GTx-104 offers a convenient IV delivery, potentially eliminating the need for nasogastric tube administration and reducing food effects, drug-to-drug interactions, and dosing errors.

Negatives

• There were more deaths in the GTx-104 arm (8 deaths) compared to the oral nimodipine arm (4 deaths) in the STRIVE-ON trial, although all deaths were determined to be due to the severity of the patients' underlying disease and not related to the drug.

Risks

• The success and timing of regulatory submissions and the ultimate outcome and timing of the NDA application for GTx-104.
• Potential changes to regulatory requirements or developments in regulatory pathways.
• The Company's ability to maintain effective patent rights and other intellectual property protection for its product candidates.
• Impact of legislative, regulatory, political, and economic developments on the company's operations and prospects.
• Actual results and the timing of events could differ materially from forward-looking statements due to various inherent risks and uncertainties.

Future Outlook

Grace Therapeutics anticipates engaging closely with the FDA throughout the review process for GTx-104. The company believes GTx-104 has a very promising role as a potential breakthrough for aSAH patients, offering improved clinical outcomes and both medical and pharmacoeconomic benefits. They expect the Orphan Drug Designation to provide seven years of marketing exclusivity upon FDA approval, further bolstered by their extensive patent estate protecting the drug's market value.

Management Comments

• "The submission of our NDA for GTx-104 for the treatment of aSAH is a significant milestone for Grace Therapeutics, built on more than a decade of painstaking research and innovation." Prashant Kohli, Chief Executive Officer.
• "Our NDA is supported by a robust data package including positive results from our STRIVE-ON trial, which provide support for improved clinical outcomes in aSAH patients and both medical and pharmacoeconomic evidence of the potential benefit of GTx-104 in the treatment of aSAH." Prashant Kohli, Chief Executive Officer.
• "The standard of care for aSAH has not seen meaningful innovation in nearly 40 years, and we believe these results point to a very promising role for GTx-104 as a potential breakthrough for the care of aSAH patients." Prashant Kohli, Chief Executive Officer.
• "We look forward to engaging with the FDA during the review process." Prashant Kohli, Chief Executive Officer.

Industry Context

The announcement positions GTx-104 as a significant potential advancement in the treatment of aneurysmal subarachnoid hemorrhage (aSAH), a severe and relatively uncommon type of stroke affecting approximately 42,500 U.S. hospital-treated patients annually. Given that the standard of care for aSAH has seen little meaningful innovation in nearly 40 years, GTx-104's novel IV formulation and positive Phase 3 data address a critical unmet medical need within the neurological and stroke treatment landscape.

Comparison to Industry Standards

• GTx-104 was directly compared against orally administered nimodipine, the current standard of care for aSAH, in the Phase 3 STRIVE-ON safety trial.
• GTx-104 demonstrated a 19% reduction in at least one incidence of clinically significant hypotension (28%) compared to oral nimodipine (35%).
• 54% of patients receiving GTx-104 achieved a relative dose intensity (RDI) of 95% or higher, significantly outperforming oral nimodipine, where only 8% achieved this RDI.
• 29% more patients on GTx-104 had favorable functional outcomes at 90 days compared to those on oral nimodipine.
• Patients receiving GTx-104 experienced fewer intensive care unit (ICU) readmissions, ICU days, and ventilator days compared to the oral nimodipine group.
• Adverse events were comparable between the two arms, with no new safety issues identified for GTx-104.
• GTx-104's unique nanoparticle technology facilitates aqueous formulation for standard peripheral IV infusion, offering a more convenient and potentially safer delivery method compared to oral nimodipine, which often requires nasogastric tube administration for unconscious or dysphagic patients and is susceptible to food effects and drug-to-drug interactions.

Stakeholder Impact

• Shareholders: Positive impact due to significant progress towards commercialization of a lead drug, potential for increased share value upon approval, and potential capital infusion from warrant exercise.
• Patients (aSAH): Potential for a new, improved treatment option that may lead to better clinical outcomes, reduced complications (hypotension), and more convenient administration.
• Healthcare Providers: Potential for a new, more effective, and easier-to-administer treatment for aSAH patients, potentially reducing ICU burden.
• Employees: Positive impact due to company progress and potential for future growth and stability.

Next Steps

• Grace Therapeutics will engage with the FDA during the NDA review process.
• The FDA typically has a 60-day period to determine if the NDA is complete and acceptable for filing.
• Potential exercise of warrants upon FDA acceptance of the NDA for review.

Key Dates

Recommendation

Keywords

Grace Therapeutics, GTx-104, New Drug Application, NDA, FDA, aneurysmal subarachnoid hemorrhage, aSAH, nimodipine, IV infusion, STRIVE-ON trial, Phase 3, Orphan Drug Designation, biopharma, clinical-stage, drug development, rare disease, neurological disorder, stroke